UMR Animal Santé Territoires Risque Environnement (CIRAD, INRAe, Univ Montpellier), Montpellier, France.
Nosocomial infection Unit, Felix-Guyon University hospital, La Reunion, Saint-Denis, France.
BMC Public Health. 2020 Oct 1;20(1):1488. doi: 10.1186/s12889-020-09591-8.
In 2015, antimicrobial resistance was identified as a public health priority for the South-Western Indian Ocean (SWIO) (i.e. Comoros, Madagascar, Mauritius, Mayotte (France), Reunion Island (France), and Seychelles). However, in 2020, colonization rates of antimicrobial-resistant bacteria (ARB) in human populations on most islands in SWIO were still not known and neither hospital nor community colonization rates had been estimated. The aim of this study was to estimate the prevalence of colonization of six ARB groups in hospitalized patients residing in the SWIO territories. The six groups comprise extended-spectrum betalactamase producing Enterobacteriaceae (ESBL-E), carbapenem-resistant Enterobacteriaceae (CRE), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and both ceftazidime and/or imipenem-resistant Acinetobacter spp. (ACB), and ceftazidime and/or imipenem-resistant Pseudomonas spp. (PSA)).
Based on comprehensive hospital laboratory ARB screening data, we provide the first estimation of ARB colonization rates in hospitalized patients residing in SWIO (2015-2017). Using ARB colonization rates in Reunion Island (France) as the reference for estimating odds ratio, we identified at risk patients based on their territory of residence.
The survey pointed to significantly higher overall ARB colonization rates in patients from Comoros, Madagascar, Mayotte, and Seychelles compared to Reunion Island as the reference. Extended-spectrum betalactamase producing Enterobacteriaceae was found to be the most common ARB group colonizing patients from SWIO territories. The highest MRSA colonization rates were observed in patients from Mayotte and Seychelles. Colonization by carbapenem-resistant Enterobacteriaceae (CRE) was highest in patients from Mauritius.
These results identify high ARB colonization rates in hospitalized patients from SWIO territories that require further investigation, particularly CRE in Mauritius and MRSA in Seychelles and Mayotte. This study is the first step toward the implementation of a broader regional ARB surveillance system.
2015 年,抗微生物药物耐药性被确定为西南印度洋地区(SWIO,包括科摩罗、马达加斯加、毛里求斯、马约特岛(法国)、留尼汪岛(法国)和塞舌尔)的公共卫生重点。然而,到 2020 年,SWIO 大多数岛屿上人群中抗微生物药物耐药细菌(ARB)的定植率仍不清楚,医院和社区定植率也尚未得到估计。本研究旨在估计 SWIO 地区住院患者中六种 ARB 定植率。这六组包括产超广谱β-内酰胺酶肠杆菌科(ESBL-E)、耐碳青霉烯肠杆菌科(CRE)、耐甲氧西林金黄色葡萄球菌(MRSA)、万古霉素耐药肠球菌(VRE)以及头孢他啶和/或亚胺培南耐药不动杆菌属(ACB)和头孢他啶和/或亚胺培南耐药假单胞菌属(PSA))。
根据全面的医院实验室 ARB 筛查数据,我们首次提供了 SWIO 地区住院患者 ARB 定植率的估计值(2015-2017 年)。使用留尼汪岛(法国)的 ARB 定植率作为估计比值比的参考,我们根据患者的居住地区确定了高危患者。
调查显示,与留尼汪岛(法国)作为参考相比,来自科摩罗、马达加斯加、马约特岛和塞舌尔的患者的总体 ARB 定植率明显更高。产超广谱β-内酰胺酶肠杆菌科是定植 SWIO 地区患者的最常见 ARB 组。马约特岛和塞舌尔的患者中观察到最高的 MRSA 定植率。来自毛里求斯的患者中,耐碳青霉烯肠杆菌科(CRE)的定植率最高。
这些结果表明,SWIO 地区住院患者中 ARB 定植率较高,需要进一步调查,特别是毛里求斯的 CRE 和塞舌尔和马约特岛的 MRSA。本研究是实施更广泛的区域 ARB 监测系统的第一步。